Disease severity, as measured by validated, patient‐reported symptom score · patients with chronic rhinosinusitis with nasal polyps
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events · patients with chronic rhinosinusitis with nasal polyps
It is very uncertain whether anti‐IgE mAb (omalizumab) changes serious adverse events compared with placebo (on top of topical steroids) (very low certainty).
1 finding from 1 review
Disease severity ‐ VAS (range 0 to 10, lower = better) · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Avoidance of surgery Nasal polyp score ≤4 (≤ 2 on each side) and an improvement in SNOT‐22 score of ≥ 8.9 points · patients with chronic rhinosinusitis with nasal polyps
Anti‐IgE mAb (omalizumab) may leads to higher avoidance of surgery Nasal polyp score ≤4 (≤ 2 on each side) and an… compared with placebo (on top of topical steroids) (low certainty).
1 finding from 1 review
Extent of disease ‐ endoscopic score · patients with chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Extent of disease ‐ CT scan (lower score = better) · patients with chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Generic quality of life measures · patients with chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Adverse events ‐ nasopharyngitis, including sore throat · patients with chronic rhinosinusitis with nasal polyps
Anti‐IgE mAb (omalizumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat compared with placebo (on top of topical steroids) (low certainty).
1 finding from 1 review
Serious adverse events · patients with severe chronic rhinosinusitis with nasal polyps
Anti‐IL‐4Rα mAb (dupilumab) may leads to lower serious adverse events compared with placebo (on top of topical steroids) (low certainty).
1 finding from 1 review
Avoidance of surgery ‐ number of patients who had surgery as rescue treatment · patients with severe chronic rhinosinusitis with nasal polyps
Anti‐IL‐4Rα mAb (dupilumab) probably leads to lower avoidance of surgery ‐ number of patients who had surgery as rescue… compared with placebo (on top of topical steroids) (moderate certainty).
1 finding from 1 review
Extent of disease ‐ endoscopic score · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Extent of disease ‐ CT scan (lower score = better) · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Generic quality of life measures · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Adverse events ‐ nasopharyngitis, including sore throat · patients with severe chronic rhinosinusitis with nasal polyps
Anti‐IL‐4Rα mAb (dupilumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat (longest… compared with placebo (on top of topical steroids) (low certainty).
1 finding from 1 review
Disease‐specific quality of life · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Resolution of symptoms · epidemic keratoconjunctivitis
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Proportion of participants with resolution of signs within 7 days of treatment (higher is favored) · epidemic keratoconjunctivitis
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Proportion of eyes in which SEI had developed within 21 days of treatment (lower is favored) · epidemic keratoconjunctivitis
It is very uncertain whether any intervention changes proportion of eyes in which SEI had developed within 21 days of… compared with steroid alone or plus levofloxacin (very low certainty).
1 finding from 1 review
Proportion of participants in whose eyes SEI had disappeared within 21 days of treatment (higher is favored) · epidemic keratoconjunctivitis
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Proportion of participants who discontinued medication and did not develop rebound SEI within 21 days (higher is favored) · epidemic keratoconjunctivitis
It is very uncertain whether any intervention changes proportion of participants who discontinued medication and did not… compared with steroid alone or plus levofloxacin (very low certainty).
1 finding from 1 review